7.6 C
New York
Thursday, April 25, 2024
HomeMarkets
Markets

InterMune’s Roche Deal Sends Peer Group Up

By Insider Scoop
0
9
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

Related ITMN
Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)
S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally
Time to Play China's Semi-Hot Real-Estate Market? (Fox Business)

InterMune's (NASDAQ: ITMN) agreement to be acquired by Roche (OTC: RHHBY) for $74 a share sent similar drug development companies up in early trading Monday.

InterMune gained 35 percent to $73.08.

  • Infinity Pharmaceuticals (NASDAQ: INFI) rose more than four percent to $11.42
  • Gilead Sciences (NASDAQ: GILD) picked up three percent to $107.10
  • Synta Pharmaceuticals (NASDAQ: SNTA) gained nearly three percent to $4.11
  • Rigel Pharmaceuticals (NASDAQ: RIGL) gained two percent to $2.64.

InterMune, which makes a single product for treatment of pulmonary fibrosis approved only in Europe and Canada, had been rumored for sale as early as March.

Talk surfaced again earlier this month, with the mention of potential acquirers including Sanofi, GlaxoSmithKline and Actelion.

Roche finally inked an $8.3 billion deal Sunday.

Posted-In: News Rumors M&A Intraday Update

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,325FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024
0
Would love your thoughts, please comment.x
()
x